Health

You can smell a regulatory panic from three aisles over, somewhere between the dusty civics textbooks and the court dockets nobody reads until the day something goes wrong. The pattern rarely changes: a hot new product, a fast market, a slow bureaucracy, and consumers learning the fine print after they have already signed up for autopay.

FDA sends 30 warning letters over marketing of compounded GLP-1 weight-loss drugs

On March 3, the Food and Drug Administration announced it had issued 30 warning letters to telehealth companies over what it described as false or misleading claims about compounded GLP-1 products advertised on their websites. The FDA said the big problems were marketing that implied compounded products were the same as FDA-approved drugs, and marketing that obscured where the drugs came from, including branding that could make consumers think the telehealth company itself was the compounder.

The agency also underlined a point that should not require underlining: compounded drugs are not FDA-approved, and they are not the same thing as FDA-approved generics. The FDA does not pre-review compounded drugs for safety, effectiveness, or quality before they are marketed. If you choose a compounded product, you should be doing it with your eyes open, not because a website sprinkled the word same around like parmesan.

Trade press coverage adds the procedural teeth: targeted firms are told to address the FDA’s concerns within a short window, and the agency warns it can pursue enforcement actions if they do not. Not a polite reminder. More like the librarian tapping the sign that says QUIET and also PLEASE RETURN THE BOOKS OR WE WILL CLOSE YOUR ACCOUNT.

What happened, in plain English

GLP-1 drugs have been a modern miracle for many patients, especially for diabetes and obesity. They have also been a modern mess in supply and pricing. That mess helped create a market for compounded versions, often distributed through telehealth pipelines that can move faster than your primary care office can answer the phone.

Compounding has a legitimate place in medicine, including when a patient needs a specific formulation or a shortage blocks access to the standard product. But it becomes a different creature when the business model is mass marketing a copycat and nudging the public into believing they are basically getting the branded product, just cheaper and faster.

The tradeoff: consumer protection vs. access

I want the FDA to crack down on misleading claims. Misleading drug marketing is not a partisan personality quiz. If a company is implying regulatory sameness where there is no FDA-reviewed sameness, that is a consumer-protection problem.

But I also want us to admit what makes this market possible. People are not chasing compounded GLP-1s because they enjoy regulatory gray zones. They are chasing them because the official route often costs too much, takes too long, or comes wrapped in insurance hurdles designed like an obstacle course built by someone who hates knees.

The Paine test, the Orwell check, and the liberty ledger

• The Paine test: truth-in-advertising enforcement can expand liberty by improving informed consent. But if enforcement becomes a substitute for fixing price-and-access reality, power concentrates and trust erodes.
• The Orwell check: watch the euphemisms, especially “personalization” and “same.” Language that blurs oversight and evidence is doing more work than it should.
• The liberty ledger: patients gain when disclosures are clear about what the product is, who made it, and what oversight exists. Patients lose if options shrink while FDA-approved options remain financially out of reach.

Guardrails that would make this feel less like theater

If we want more than a headline cycle: publish the warning letters in a searchable, readable way with plain-English summaries; focus enforcement on deception and unsafe practices, not lawful compounding for genuine clinical need; and push policy that targets the incentives driving people into gray markets, including drug pricing and coverage design.

So yes: police misleading marketing. But if Americans keep needing workarounds to obtain mainstream medications, the workarounds are not the scandal. The system is. Are we going to fix the price-and-access reality that created this GLP-1 gold rush, or just keep yelling at the prospectors?

I was in the kind of municipal building where the air smells like paper, rubber stamps, and decisions made at 11:58 p.m. The bulletin board was pure civic routine: a lost cat, a zoning notice, and a laminated warning about something that is always, somehow, for our safety.

Then I read about glass. Not metaphorical glass, like transparency. Actual glass. The kind that does not belong in dinner.

USDA recall update: nearly 37 million pounds

On March 3, the U.S. Department of Agriculture’s Food Safety and Inspection Service said Ajinomoto Foods North America expanded a recall tied to possible glass contamination. The update added roughly 33.6 million pounds of ready-to-eat and not-ready-to-eat frozen products, bringing the total to about 36.99 million pounds.

The affected items include chicken and pork fried rice, ramen, and shu mai dumplings sold under multiple brand names, including Ajinomoto, Kroger, Ling Ling, Tai Pei, and Trader Joe’s. The products were produced from October 21, 2024 through February 26, 2026, shipped to retail locations nationwide, and some were exported to Canada and Mexico. As of reports citing the FSIS update, no confirmed injuries had been reported.

Ajinomoto, after investigating consumer complaints, determined that carrots used as an ingredient were the likely source of the glass contamination. Yes, carrots. The orange stick you hand to toddlers as a peace offering. In 2026, that carrot can apparently empty freezers across a continent.

This expanded action stacks on top of the earlier February 19 FSIS-announced recall of about 3.37 million pounds of frozen chicken fried rice products, also tied to possible glass. The plotline is familiar: complaint, investigation, expansion, and that polite modern phrase that means everyone is scrambling: voluntary recall.

The tradeoff: convenience dinners, centralized risk

We built a food system optimized for speed and sameness. That is not a moral failing. It is the logical endpoint of busy lives and long commutes.

But convenience comes with a shadow invoice. When production is centralized, a single ingredient runs through an industrial river. If something goes wrong upstream, it does not stay local. It goes national, sometimes international, before the first worried customer figures out why their mouth feels like a hardware aisle.

And the public is asked to manage the last mile of safety with the least amount of information: check your freezer, find the establishment number, compare dates, do not eat, return or discard. It is like being handed a court docket and told to practice law in the parking lot.

Liberty ledger, Orwell check, Paine test

The liberty ledger: the public gains notice, but also inherits paperwork. People with the least slack are asked to throw away food, drive back to a store, or gamble that their particular bag is not the one with the invisible hazard.

The Orwell check: food safety language is soothing: voluntary, precautionary, out of an abundance of caution. Sometimes it is honest. Sometimes it is a whisper while the building is on fire.

The Paine test: does the response expand liberty or concentrate power? A strong food safety system expands liberty by letting people buy food without becoming part-time forensic accountants. A lazy response concentrates power by keeping the industrial pipeline opaque while shifting risk management onto households.

So yes, demand the boring stuff that prevents the dramatic stuff: fund inspection and modern traceability tools with strict privacy guardrails, publish clearer recall data normal people can use, insist on audits that have teeth, and make refunds simple and proactive. We can have convenience and safety, but we cannot keep pretending a mega-scale food system will police itself forever. If a carrot can do this much damage, what exactly are we waiting for before we tighten the guardrails?

I have seen this routine in the burnt-coffee committee rooms: a speech about “lean government,” followed by a purchase order for a brand-new bureaucracy. Medicaid is supposed to be health care. The current push is to build a machine that measures virtue with a timesheet.

Spend millions to “save” money

The Associated Press reported this week that states face large up-front costs to comply with Medicaid eligibility mandates tied to work or similar activities. The irony is not subtle: to prove you are serious about saving money, you first spend a lot of it.

Based on the AP’s review of budget projections in more than 25 states, technology upgrades and extra staffing are likely to exceed $1 billion. A $200 million federal allotment is already flowing to help implementation, but it does not cover the whole project.

Who gets targeted, and how often they must prove it

In most states, the requirements described would apply to adults ages 19 to 64 without young children whose incomes are above the typical eligibility cutoff. They would need to show at least 80 hours a month of work or community service, or enroll at least half-time as a student. Eligibility reviews would shift from annual to every six months, meaning the paperwork clock ticks twice as often.

Washington says the point is savings. The Congressional Budget Office estimate cited by the AP projects $388 billion in federal savings over a decade, alongside 6 million fewer people with health insurance. That is the tradeoff in plain numbers.

The practical snag: states do not have the data

Most states do not currently collect employment or education information from Medicaid participants, so they must build portals, redesign eligibility systems, set up data checks, train staff, and hire contractors. Examples cited include:

• Missouri: a fast-tracked $32 million appropriation and about 120 workers costing $12.5 million.
• Maryland: more than $32 million in combined state and federal spending.
• Kentucky: more than $46 million.
• Colorado: more than $51 million.
• Arizona: $65 million and roughly 150 additional staff.

Meanwhile, key exceptions, including who qualifies as medically frail, are not planned to be defined until rules due in June. States are being asked to pour a foundation before they receive the blueprint.

The Orwell check and the liberty ledger

My Orwell check: the language comes in soft. Work requirements become “community engagement.” Disenrollment becomes “program integrity.” Extra paperwork becomes “dignity.” But the system runs on compliance.

Liberty ledger: vendors and contractors get a new market; agencies get new systems and headcount; politicians get a tidy talking point. The people most likely to lose coverage are those with unstable hours, limited internet access, or health problems that are real but hard to document neatly, especially while states wait on the medically frail definition.

Georgia is currently the only state requiring some Medicaid recipients to work under its Pathways to Coverage program. A Government Accountability Office report found Georgia spent $54.2 million on administrative costs between October 2020 and March 2025, mostly financed by federal dollars.

The Paine test and the tradeoff

The Paine test: does this expand liberty, or concentrate power? Conditioning health coverage on a reporting regime concentrates power and turns coverage into a bureaucratic correctness contest. If the goal is savings, the public deserves hard numbers: projected costs, vendor contracts, error rates, and appeal timelines, not slogans. And with federal penalties for too many Medicaid payment errors starting in October 2029, states will feel pressure to overbuild controls now.

I spent part of yesterday in that classic American policy workshop: a fluorescent-lit corner of the public library, Federal Register open, printer toner in the air, civic dread on the menu. In my head: a senior with a walker, a kid with braces, a veteran with a CPAP. On screen: Washington trying to stop scams without jamming up care.

What CMS did (and when)

CMS imposed a six-month, nationwide moratorium on new Medicare enrollments for certain durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) suppliers, specifically the supplier category it calls medical supply company suppliers. The notice says it takes effect February 27, 2026 and applies across the United States, including territories and the District of Columbia.

• New businesses whose principal function is furnishing DMEPOS supplies cannot newly enroll under the covered supplier types during the moratorium.
• Existing enrolled suppliers that need a new initial enrollment (for example, a new practice location that requires separate enrollment) also hit a locked door for six months.
• Applications received by contractors before the effective date are not supposed to be swept into the ban.

CMS lists seven affected supplier types, all variations of “medical supply company,” including versions staffed with orthotics, pedorthics, prosthetics, combinations of those, and versions with a registered pharmacist or a respiratory therapist. CMS says it will closely screen applications during the moratorium to stop would-be medical supply companies from slipping in through another category, and it explicitly mentions site visits and online research. It also warns about long reapplication or reenrollment bars and referrals when suppliers submit false or misleading information.

The Orwell check: “moratorium” is a ban with nicer shoes

“Moratorium” is the polite noun. “Temporary” is the comforting adjective. Together they read like a sweater you put on so you do not notice the handcuffs.

Yes, CMS points to authority to impose temporary enrollment moratoria when it determines there is significant potential for fraud, waste, or abuse, and it has to explain itself in a Federal Register notice. That is the civics-textbook version. The lived version is a nationwide enrollment ban, even a narrow one, is a big lever.

The tradeoff and the liberty ledger

CMS frames this as a fraud move, not a benefit cut: existing suppliers can keep billing. Other kinds of suppliers that furnish DMEPOS but do not have DMEPOS as their principal function (like pharmacies and hospitals) are not the target. CMS also leaves room for states to decide how, or whether, to mirror a similar moratorium in Medicaid and CHIP.

Who gains freedom? Beneficiaries and taxpayers, if fewer scams get through. Honest providers, if scammers stop undercutting the market. Who loses freedom? Clean new entrants, for six months, and communities with thin supplier networks that rely on competition and choice. And the system takes on more executive discretion, especially because the notice acknowledges the moratorium can be extended in six-month increments.

Guardrails worth demanding

• Publish monthly metrics that justify the moratorium and track collateral damage.
• Provide a clear, fast appeal and correction path for legitimate suppliers caught in gray zones.
• Congress should demand oversight review from inspectors general and GAO on whether a nationwide moratorium beats more targeted tools.
• Put an exit ramp in writing: a public standard for lifting the moratorium, and real specificity for any extension.

Fraud is a tax on care. But so is unaccountable power. Are we going to demand the guardrails now, or pretend “temporary” always means what it says?

I was in a library once, thumbing through a dusty local-court digest, when it hit me how much of American life is decided by people you never meet using rules you never see. Not a conspiracy. A filing system. In healthcare, the filing system has a co-pay.

What the FDA did (in public, on the record)

On February 25, 2026, the Food and Drug Administration approved Dupixent (dupilumab) for adults and children ages 6 and up with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. The FDA calls it the first approval for the condition.

AFRS is not your garden-variety stuffy-nose season. The FDA describes it as an uncommon, chronic sinus inflammation driven by an allergic reaction to fungi in the sinuses, with thick, sticky mucus. It can include expansion of the sinuses and erosion of surrounding bone, and in severe cases can push toward the eye area or brain. At that point your body stops being a body and starts being a construction site.

The FDA says the approval was supported by a 52-week study in patients 6 years and older. The agency points to improvements on CT scan scoring for sinus opacification, plus improvements in measures like nasal polyp size, congestion, and sense of smell. It also highlights reduced need for systemic corticosteroids and sinus surgery compared with placebo, and notes the safety profile looked consistent with what is already known for the drug.

That is the part I can respect: the referee blew the whistle, dated the page, and made a new play legal.

The tradeoff: progress paid for with paperwork and privacy

Here is the part that never makes the celebratory press release. In modern American medicine, FDA approval is often the start of the argument, not the end. The real gate swings on coverage, prior authorization, and the fine print of “medical necessity.”

And those gates are built out of patient data. If you want a high-cost biologic, the system often wants a biography:

• Imaging
• Procedure history
• Medication history
• Symptoms translated into billing codes

The approved indication includes a history of sino-nasal surgery. That is clinically meaningful, and also administratively irresistible. It turns your chart into a passport that has to be stamped, photocopied, and re-stamped until you either get the drug or run out of time.

The Orwell check: when delay wears a lab coat

Listen to the euphemisms and you can hear the power moving: “utilization management,” “benefits determination,” “step therapy,” “site of care optimization.” Translate it and a lot of it reads: prove you are sick enough, again, to someone who will not meet you.

The FDA did its job in public. The payer side too often does its job in private, with criteria you only see after you have been denied. That is a due process problem dressed up as a customer-service issue.

The liberty ledger (who gains, who loses)

• Patients gain a new, FDA-approved option that could mean fewer surgeries or fewer courses of systemic steroids.
• Clinicians gain another tool authorized for the problem at hand, which can matter when coverage fights multiply.
• Insurers and plan administrators gain a clearer box to build policies around, for better or worse.
• The public gains the possibility of fewer repeat surgeries and complications, and inherits the bill and the temptation to ration through delay.

The approval expands the menu. The fight is whether the menu becomes a meal or just a laminated tease.

The Paine test, and the guardrails that would make this real

The Paine test is simple: does the next phase expand a patient’s practical freedom to get appropriate care, or concentrate power in the hands of whoever controls the paperwork?

• Transparency: coverage criteria should be public, plain-language, and stable.
• Speed with teeth: appeals should move on timelines that match a patient’s life; when deadlines are missed, the default should not be “wait longer.”
• Data minimization: request the narrowest slice of information necessary, not a full medical autobiography.
• Oversight: treat prior authorization and documentation demands like the quasi-judicial system they are.

The FDA did the public part. Now the rest of government should do the boring part: rules, audits, enforcement, sunlight. Because if a life-changing therapy exists on paper but not in practice, we have not solved a medical problem. We have just invented a new reason to stand in line.

So here is my question: should access to an FDA-approved treatment hinge more on clinical need, or on how much private information you are willing to surrender to prove you deserve it?

There is a particular sound a lawsuit makes when it hits the public square: not a bang, a thud. Inside the courthouse, the drama is rarely “who’s right.” It is usually “who had the authority,” “what process was required,” and “did anyone actually follow it.” That is the unglamorous plumbing where liberty tends to live.

What the states say happened

On February 24, a coalition of states filed suit in federal court in the Northern District of California against HHS Secretary Robert F. Kennedy Jr., HHS, acting CDC Director Jayanta Bhattacharya, and the CDC. The complaint targets what it calls a January 5 CDC “Decision Memo” that removed seven vaccines from universally recommended status.

• rotavirus
• meningococcal disease
• hepatitis A
• hepatitis B
• influenza
• COVID-19
• RSV

The states ask the court to declare the new schedule unlawful and set it aside. They also challenge changes to the vaccine advisory committee itself. Yes, we are litigating the childhood immunization schedule now. America: where even pediatric guidance can become a federal case.

Process, not just policy

The complaint’s core theory is procedural. It alleges that after the administration replaced the Advisory Committee on Immunization Practices (ACIP), the CDC bypassed the traditional expert-driven recommendation pathway. It also claims the January 5 memo was presented to the then-acting CDC director by senior officials including the NIH director, the CMS administrator, and the FDA commissioner, and that it was signed the same day. Efficient teamwork, maybe. Or a midnight committee room where letterhead substitutes for deliberation.

AP reports more than a dozen states argue the rollback threatens public health and will raise costs for states facing outbreaks and downstream effects of lower vaccination rates. The administration has dismissed the lawsuit as political. Courts, as usual, are being asked to translate feelings into law.

The Orwell check: “shared decision-making” vs. shared confusion

Moving decisions into the doctor-patient conversation can sound like autonomy. But a slogan is not a system. Demoting a federal recommendation can shift how schools, insurers, public health departments, and parents read what is normal, expected, and covered. The complaint argues that “talk to your clinician” is not much of a plan where access to primary care is uneven.

The liberty ledger: who loses clarity and coverage?

The states argue ACIP recommendations are wired into federal statutes and programs. They point to Medicaid and CHIP coverage rules tied to ACIP, the Affordable Care Act’s requirement that insurers cover ACIP-recommended vaccines without cost-sharing, and the Vaccines for Children program’s reliance on ACIP-linked standards for eligible kids. Translation: recommendation categories are not just messaging. They are infrastructure.

There is also a privacy angle lurking in the weeds. When policy turns chaotic, outbreak response can mean more verification pressure for schools and clinics, and more “temporary” measures that never feel temporary in the rearview mirror.

The Paine test and the tradeoff

The pro-liberty question is not reflexively pro-mandate or reflexively anti-vaccine. It is pro-guardrails. If the government wants to change major recommendations, it should do it the hard way: show the evidence, run the lawful advisory process, publish the reasoning, and take the heat.

Now the courts will weigh in, and Congress should not outsource the entire mess to litigation. Oversight hearings, inspector general reviews, and clear statutory rules for how guidance is made are boring. Boring is the point. One question for the civic ledger: if we can rewrite the childhood vaccine schedule by memo and muscle, what other shortcuts are we learning to tolerate next?

I spent part of last night in the familiar civic perfume: old paper, stale coffee, and that courthouse-air scent of people arguing about money while insisting it is about principles. A docket is never just a docket. It is a weather report for the rest of us.

What HRSA just did

HRSA (inside HHS) has put the 340B rebate model back on the table by publishing a Request for Information in the Federal Register on February 17, 2026. The comment deadline is March 19, 2026.

The agency is asking for input on the operational guts of a potential 340B rebate model pilot: costs, cash-flow impacts, reporting, data collection, and even how rebates might be denied. Translated into plain English: this sketches a system where covered entities could pay full price up front and later get the 340B price difference back as a rebate.

Why this is happening (again)

HRSA also notes that the U.S. District Court for the District of Maine, on February 10, 2026, vacated and remanded earlier 340B Rebate Model Pilot Program application notices and related manufacturer approvals. And in a February 5 court filing described by the American Hospital Association, HHS said it would scrap the existing rebate pilot and consider restarting the administrative process.

So yes, the paperwork is back. The question is what it buys besides more paperwork.

The tradeoff: transparency for whom, leverage over whom?

Manufacturers and allies frame a rebate model as a cleanup tool: more transparency, fewer duplicate discounts. Safety-net providers answer with blunt arithmetic: if you replace an immediate discount with a delayed rebate, you turn a statutory benefit into a cash-flow bet, with rural and thin-margin facilities cast as involuntary lenders.

This matters because 340B is not small beer. Axios reports the program covers more than $81 billion in annual drug purchases. When the number is that big, every tweak grows its own industry, and every industry hires a choir.

The Paine test and the Orwell check

The Paine test: does this expand liberty in the health system, meaning more predictable access and rules, or does it concentrate power by adding new levers and new compliance costs?

The Orwell check: notice how “discount” becomes “rebate.” A discount is legible and immediate. A rebate is conditional and slow, with homework attached. HRSA is explicitly asking about staffing, systems, reporting, and data collection. When you need elaborate infrastructure to receive what the statute already promises, you are building a compliance regime, not just “improving transparency.”

Guardrails, before the next court date

The American Hospital Association and other groups, in a February 19, 2026 letter to HRSA, asked to extend the comment period to April 20, 2026, arguing the current window is too short to answer dozens of detailed questions with facts and evidence.

If this idea is going to survive, it needs sunlight and guardrails: a serious comment window, published assumptions, and a uniform, auditable, fast rebate timeline with consequences for late payment. If new data flows are required, HRSA should be explicit about what is required, what is prohibited, and how patient privacy is protected in practice.

And, better yet, Congress should clarify the rules for 340B in statute instead of outsourcing policy to an accounting trick. So here is the question: do you want 340B to be a clean discount that supports the safety net, or a rebate maze where the strongest balance sheets win?

I have seen this policy fight before: a warm committee room, thick folders, and everyone insisting they are the last adult in the building. The only honest witness is the clock, counting down to the agency deadline while the rest of Washington argues about motives.

The latest sequel is the 340B Drug Pricing Program, where a discount, a hospital balance sheet, and a patient in a waiting room all end up sharing the same nervous system.

What happened (dates, docket, deadline)

The verified spine: the Health Resources and Services Administration (HRSA), inside HHS, published a Request for Information (RFI) on February 17, 2026 about a potential 340B Rebate Model Pilot Program. HRSA is asking whether, and how, to shift from upfront discounts to a rebate approach, what standards should govern manufacturer rebate plans, and what the downstream impacts would be across the drug supply chain. Comments are due March 19, 2026.

Axios reported that the administration is taking another swing at reshaping 340B with the rebate idea after litigation and court setbacks. Hospital groups led by the American Hospital Association sent HRSA a letter dated February 19, 2026 asking to extend the comment timeline until April 20, 2026, arguing the current window is too short for meaningful, evidence-backed responses.

The Orwell check: “rebate model” as a polite name for a cash-flow squeeze

“Rebate model” sounds like a coupon. Operationally, it can mean covered entities pay full price upfront, then wait for the difference after verification and reconciliation. For a well-capitalized system, that lag is manageable. For safety-net providers, the lag is oxygen.

Manufacturers have a real complaint too: the program is large, complicated, and often litigated, and they argue they need better tools to prevent what the RFI calls duplicate discounts and diversion. Fine. But the fix cannot be “make the provider be the bank.”

The tradeoff: integrity and transparency vs. access and administrative drag

HRSA’s questions put the tension on paper: administrative costs, staffing impacts, IT systems, the risk of rebate denials, and the cash-flow consequences of waiting for money that used to be embedded in the purchase price. The RFI also probes guardrails for denials, reporting, and how to balance stakeholder concerns with the agency’s desire to test rebates, including timing ideas such as rebates (or documented denials) within 10 calendar days of data submission.

The liberty ledger: leverage, discretion, and data

On the gain side, a rebate model could offer manufacturers a more standardized way to validate claims, reduce duplicate discounts, generate data policymakers say they need, and potentially increase transparency.

On the loss side, covered entities could be forced to front costs and chase rebates. And the RFI directly raises privacy and security concerns tied to patient information and data submission, including whether agreements with third parties are needed. Translation: to run rebates at scale, more claims-level data may move more widely, more often, to more places.

The Paine test: does this expand liberty or concentrate power? A system that rewards whoever can wait the longest and dispute the hardest starts to look like leverage with excellent paperwork.

Guardrails that should be non-negotiable

• Hard, enforceable payment deadlines and a real appeals path for denials.
• Narrow, auditable, transparent denial standards.
• Privacy by design: minimal necessary data, encryption, access controls, clear retention limits.
• Public outcome measures people can understand, not just compliance metrics.
• Respect for process, including the request for more time to comment.

Closing question: if 340B is rebuilt, who is being asked to front the money, front the data, and front the risk while everyone else fronts the rhetoric?

I was sitting in a library, breathing that public-building perfume of dust, toner, and municipal optimism, reading an FDA letter that felt like it was drafted in a midnight committee room. Not the cinematic midnight. The paperwork midnight, where the coffee is cold and the euphemisms are piping hot.

The topic: food dyes. The mechanism: enforcement discretion. The result: a marketing green light dressed up as a public-health win.

What the FDA changed

On February 5, the FDA said it will allow companies to make voluntary front-of-pack claims like “no artificial colors” when a product contains no petroleum-based, certified synthetic colors. The agency signaled this through a letter to industry, indicating it will exercise enforcement discretion under federal misbranding rules for certain claims.

That same day, FDA also approved beetroot red as a new color additive and expanded approved uses of spirulina extract. In other words: label flexibility plus more alternative color options.

Plain English: a definition moved without rulemaking

For years, the practical takeaway was simple: if you added color, you generally could not claim “no artificial colors,” even if that color came from beets or algae. Now, you can make the claim as long as you are free of certain certified synthetic dyes.

And this wasn’t done through a new binding regulation after notice and comment. It was done by the agency saying, in effect: we can deem labels misleading, but we do not intend to enforce that part here if you meet our conditions. Lawful, yes. Small, no.

The Orwell check: “artificial” stops meaning what humans think it means

Most shoppers read “no artificial colors” and hear a normal-person promise: nothing fake, nothing labby, nothing chemical. The new approach makes the claim hinge on a regulatory subset (certified petroleum-based colors), not the everyday meaning of “artificial.”

The public does not shop in the Code of Federal Regulations. The public shops under fluorescent lights at 6:40 p.m., with a hungry kid and a budget. When technical meaning and human meaning diverge, labels become vibes.

The liberty ledger: who gets clarity, who gets cover

• Consumers might gain a faster shift away from certain synthetic dyes, which some families actively want.
• Consumers also lose a clean signal. The front label gets easier to print and harder to interpret.
• Industry gains a broader badge without going color-free, and the “halo” can outpace what the product actually is.
• Government gains a talking point: action without a long rulemaking fight.

The tradeoff: nudges versus honest labeling

The FDA pairs this flexibility with safety and purity expectations for color additives and with expanded alternatives like beetroot red and spirulina extract.

But critics point to the practical problem: a “no artificial colors” claim, defined this way, can still coexist with additives shoppers do not expect. Titanium dioxide comes up for a reason: FDA describes it as a synthetically produced white pigment regulated as a color additive, and the agency notes it is reviewing a petition asking FDA to repeal the regulation allowing its use in foods.

Here’s my Paine test: does this expand liberty or concentrate power? This concentrates interpretive power in agencies and brands, and it sends citizens back to the fine print. Should “no artificial colors” mean what a shopper thinks it means, or what a regulator can defend in a footnote?

Washington has a particular talent: making raw power smell like disinfectant. Not the clean kind. More like copier toner and a midnight committee room realizing the public has started reading the footnotes. The binder snaps shut, and somebody clears a familiar phrase for reuse: standards.

This week the Food and Drug Administration did what institutions do when they stumble in public. It reversed course.

What the FDA changed, and why people notice

On February 18, 2026, after a formal back-and-forth, the FDA agreed to initiate review of Moderna’s application for a seasonal flu shot using mRNA technology, after previously refusing to even accept the filing. Moderna also revised its approach by age: it is now seeking full approval for adults ages 50 to 64, and accelerated approval for adults 65 and older, paired with a commitment to conduct an additional study in older adults. The FDA set a target decision date of August 5, 2026.

Just last week, the agency had issued a rare refusal-to-file letter. Translation: not simply “no,” but “we are not even opening the docket.” That kind of procedural lurch is where trust goes to die.

The substantive dispute (fine) vs the procedural whiplash (not fine)

The stated dispute was about trial design and what counts as an appropriate comparison, especially for seniors. Regulators argued the key study compared Moderna’s candidate to a standard-dose flu shot rather than the higher-dose shots often used for people 65 and older.

Reasonable people can debate comparators. That is what review is for. The problem is changing lanes without signaling, then calling it routine.

The Paine test

Does this expand liberty, or concentrate it in a few hands? When rules quietly tighten, then quietly loosen, “high standards” starts functioning less like a yardstick and more like a baton. Even if the motive is bureaucratic self-protection, the effect is the same: more dependence on whoever holds the microphone.

The Orwell check

Watch the euphemisms. If the agency believes seniors require a high-dose comparator, say it clearly, early, and publicly. Put it in guidance researchers can rely on before years of work and enrollment. And when the agency changes its mind, show the work.

The liberty ledger and the tradeoff

A review could eventually expand options for adults 50 and older. Options are freedom. But refusal-to-file cuts off the public process before it starts: fewer documents, fewer meetings, less scrutiny, more “trust us.” In public health, credibility does the heavy lifting downstream, shaping what employers require, what insurers cover, and what pharmacies stock.

Process is the compromise between faster innovation and safer proof. If the FDA wants high standards, good. Now deliver high explainability, too.